Indaptus Therapeutics (INDP) to Release Quarterly Earnings on Thursday

Indaptus Therapeutics (NASDAQ:INDP) is anticipated to announce its results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.87) per share for the quarter.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($3.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.36) by $1.26.

Indaptus Therapeutics Stock Performance

Shares of INDP stock opened at $2.15 on Tuesday. Indaptus Therapeutics has a fifty-two week low of $1.51 and a fifty-two week high of $19.91. The firm has a market capitalization of $4.82 million, a price-to-earnings ratio of -0.09 and a beta of 1.37. The stock’s 50-day simple moving average is $2.18 and its 200-day simple moving average is $2.43.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors own 7.06% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.